Literature DB >> 18329481

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Raja M Flores1, Harvey I Pass, Venkatraman E Seshan, Joseph Dycoco, Maureen Zakowski, Michele Carbone, Manjit S Bains, Valerie W Rusch.   

Abstract

OBJECTIVE: The optimal procedure for resection of malignant pleural mesothelioma is controversial, partly because previous analyses include small numbers of patients. We performed a multi-institutional study to increase statistical power to detect significant differences in outcome between extrapleural pneumonectomy and pleurectomy/decortication.
METHODS: Patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy or pleurectomy/decortication at 3 institutions were identified. Survival and prognostic factors were analyzed by the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis.
RESULTS: From 1990 to 2006, 663 consecutive patients (538 men and 125 women) underwent resection. The median age was 63 years (range, 26-93 years). The operative mortality was 7% for extrapleural pneumonectomy (n = 27/385) and 4% for pleurectomy/decortication (n = 13/278). Significant survival differences were seen for American Joint Committee on Cancer stages 1 to 4 (P < .001), epithelioid versus non-epithelioid histology (P < .001), extrapleural pneumonectomy versus pleurectomy/decortication (P < .001), multimodality therapy versus surgery alone (P < .001), and gender (P < .001). Multivariate analysis demonstrated a hazard rate of 1.4 for extrapleural pneumonectomy (P < .001) controlling for stage, histology, gender, and multimodality therapy.
CONCLUSION: Patients who underwent pleurectomy/decortication had a better survival than those who underwent extrapleural pneumonectomy; however, the reasons are multifactorial and subject to selection bias. At present, the choice of resection should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.

Entities:  

Mesh:

Year:  2008        PMID: 18329481     DOI: 10.1016/j.jtcvs.2007.10.054

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  150 in total

1.  Early mesothelioma revisited.

Authors:  Seiki Hasegawa
Journal:  Int J Clin Oncol       Date:  2012-01-11       Impact factor: 3.402

Review 2.  Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Authors:  Sanjana Kondola; David Manners; Anna K Nowak
Journal:  Ther Adv Respir Dis       Date:  2016-02-12       Impact factor: 4.031

3.  Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy.

Authors:  Marco Trovo; Davide Franceschini; Carlo Furlan; Francesca Pietrobon; Stefano Vagge; Eleonora Farina; Alberto Revelant; Luca Visani; Virginia Maragna; Giuseppe Parisi; Vieri Scotti
Journal:  Radiol Med       Date:  2019-04-08       Impact factor: 3.469

Review 4.  A systematic review of lung-sparing extirpative surgery for pleural mesothelioma.

Authors:  Elaine Teh; Francesca Fiorentino; Carol Tan; Tom Treasure
Journal:  J R Soc Med       Date:  2011-02       Impact factor: 5.344

5.  Which type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?

Authors:  Mehmet Ali Bedirhan; Levent Cansever; Adalet Demir; Süleyman Ceyhan; Hasan Akın; Halide Nur Urer; Aysun Olçmen; Celalettin Kocatürk; Ibrahim Dinçer
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

6.  Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Authors:  Nico van Zandwijk; Glen Reid; Anthony Linton; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

7.  Multimodality therapy for malignant pleural mesothelioma.

Authors:  Walter Weder; Isabelle Opitz
Journal:  Ann Cardiothorac Surg       Date:  2012-11

8.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 9.  What is the survival after surgery for localized malignant pleural mesothelioma?

Authors:  Sandra M Gelvez-Zapata; Daniel Gaffney; Marco Scarci; Aman S Coonar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-17

Review 10.  Photodynamic therapy for lung cancer and malignant pleural mesothelioma.

Authors:  Charles B Simone; Keith A Cengel
Journal:  Semin Oncol       Date:  2014-10-07       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.